Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
14
05
2020
revised:
17
09
2020
accepted:
08
12
2020
pubmed:
30
12
2020
medline:
25
2
2022
entrez:
29
12
2020
Statut:
ppublish
Résumé
Genome-wide association studies suggest that the combined effects of breast cancer (BC)-associated single nucleotide polymorphisms (SNPs) can improve BC risk stratification using polygenic risk scores (PRSs). The performance of PRSs in genome-wide association studies-independent clinical cohorts is poorly studied in individuals carrying mutations in moderately penetrant BC predisposition genes such as CHEK2. A total of 760 female CHEK2 mutation carriers were included; 561 women were affected with BC, of whom 74 developed metachronous contralateral BC (mCBC). For PRS calculations, 2 SNP sets covering 77 (SNP set 1, developed for BC risk stratification in women unselected for their BRCA1/2 germline mutation status) and 88 (SNP set 2, developed for BC risk stratification in female BRCA1/2 mutation carriers) BC-associated SNPs were used. All statistical tests were 2-sided. Both SNP sets provided concordant PRS results at the individual level (r = 0.91, P < 2.20 × 10-16). Weighted cohort Cox regression analyses revealed statistically significant associations of PRSs with the risk for first BC. For SNP set 1, a hazard ratio of 1.71 per SD of the PRS was observed (95% confidence interval = 1.36 to 2.15, P = 3.87 × 10-6). PRSs identify a subgroup of CHEK2 mutation carriers with a predicted lifetime risk for first BC that exceeds the surveillance thresholds defined by international guidelines. Association of PRS with mCBC was examined via Cox regression analysis (SNP set 1 hazard ratio = 1.23, 95% confidence interval = 0.86 to 1.78, P = .26). PRSs may be used to personalize risk-adapted preventive measures for women with CHEK2 mutations. Larger studies are required to assess the role of PRSs in mCBC predisposition.
Sections du résumé
BACKGROUND
Genome-wide association studies suggest that the combined effects of breast cancer (BC)-associated single nucleotide polymorphisms (SNPs) can improve BC risk stratification using polygenic risk scores (PRSs). The performance of PRSs in genome-wide association studies-independent clinical cohorts is poorly studied in individuals carrying mutations in moderately penetrant BC predisposition genes such as CHEK2.
METHODS
A total of 760 female CHEK2 mutation carriers were included; 561 women were affected with BC, of whom 74 developed metachronous contralateral BC (mCBC). For PRS calculations, 2 SNP sets covering 77 (SNP set 1, developed for BC risk stratification in women unselected for their BRCA1/2 germline mutation status) and 88 (SNP set 2, developed for BC risk stratification in female BRCA1/2 mutation carriers) BC-associated SNPs were used. All statistical tests were 2-sided.
RESULTS
Both SNP sets provided concordant PRS results at the individual level (r = 0.91, P < 2.20 × 10-16). Weighted cohort Cox regression analyses revealed statistically significant associations of PRSs with the risk for first BC. For SNP set 1, a hazard ratio of 1.71 per SD of the PRS was observed (95% confidence interval = 1.36 to 2.15, P = 3.87 × 10-6). PRSs identify a subgroup of CHEK2 mutation carriers with a predicted lifetime risk for first BC that exceeds the surveillance thresholds defined by international guidelines. Association of PRS with mCBC was examined via Cox regression analysis (SNP set 1 hazard ratio = 1.23, 95% confidence interval = 0.86 to 1.78, P = .26).
CONCLUSIONS
PRSs may be used to personalize risk-adapted preventive measures for women with CHEK2 mutations. Larger studies are required to assess the role of PRSs in mCBC predisposition.
Identifiants
pubmed: 33372680
pii: 6054801
doi: 10.1093/jnci/djaa203
pmc: PMC8246885
doi:
Substances chimiques
Checkpoint Kinase 2
EC 2.7.1.11
CHEK2 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
893-899Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Genet Epidemiol. 2005 Jul;29(1):1-11
pubmed: 15880399
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Nat Genet. 2013 Apr;45(4):345-8
pubmed: 23535722
Nat Genet. 2015 Apr;47(4):373-80
pubmed: 25751625
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):380-394
pubmed: 29382703
Lancet. 2013 May 25;381(9880):1827-34
pubmed: 23639488
Nat Genet. 2015 Feb;47(2):164-71
pubmed: 25581431
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
Nat Commun. 2020 Dec 14;11(1):6383
pubmed: 33318493
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 28521362
Bioinformatics. 2007 May 15;23(10):1294-6
pubmed: 17384015
Int J Cancer. 2019 Oct 1;145(7):1782-1797
pubmed: 31050813
J Clin Oncol. 2016 Aug 10;34(23):2750-60
pubmed: 27269948
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
J Clin Oncol. 2012 Dec 10;30(35):4308-16
pubmed: 23109706
Ann Transl Med. 2018 Apr;6(7):121
pubmed: 29955581
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Nat Genet. 2013 Apr;45(4):349-51
pubmed: 23535723
Genet Med. 2017 May;19(5):599-603
pubmed: 27711073
J Intern Med. 2012 Apr;271(4):321-30
pubmed: 22292490
Br J Cancer. 2011 May 10;104(10):1656-63
pubmed: 21468051
J Med Genet. 2016 Jul;53(7):465-71
pubmed: 26928436
J Natl Cancer Inst. 2017 Jul 1;109(7):
pubmed: 28376175